Tumor-derived IL-33 increases the number and function of CD103+CD8+ TILs, and a combination of IL-33 with the CTLA-4 and PD-1 immune checkpoint blockades synergistically prolonged the survival of tumor-bearing mice [98]. Here, IL33 is linked to neoplasm.